DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.3% – What’s Next?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC)’s stock price fell 1.3% during mid-day trading on Tuesday . The stock traded as low as $6.71 and last traded at $6.79. 131,193 shares changed hands during trading, a decline of 49% from the average session volume of 256,443 shares. The stock had previously closed at $6.88.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DMAC shares. Wall Street Zen upgraded DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. Craig Hallum lifted their price target on DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a report on Friday, July 18th. Lake Street Capital lifted their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a “buy” rating in a report on Friday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DiaMedica Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

DiaMedica Therapeutics Stock Down 1.3%

The firm has a market capitalization of $350.98 million, a price-to-earnings ratio of -9.84 and a beta of 1.40. The stock’s 50 day moving average price is $6.62 and its two-hundred day moving average price is $5.02.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). On average, equities analysts expect that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current fiscal year.

Insider Buying and Selling at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg purchased 338,265 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average cost of $6.00 per share, with a total value of $2,029,590.00. Following the completion of the purchase, the insider owned 7,654,045 shares of the company’s stock, valued at $45,924,270. The trade was a 4.62% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 1,000,000 shares of company stock valued at $5,958,598 over the last 90 days. Corporate insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Royal Bank of Canada boosted its holdings in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after purchasing an additional 154,701 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in DiaMedica Therapeutics by 374.7% in the second quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock worth $563,000 after purchasing an additional 113,893 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock worth $462,000 after purchasing an additional 52,854 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after purchasing an additional 58,457 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.